The FDA publicly promotes regulatory flexibility for rare diseases, yet industry insiders perceive it as less permissive than prior administrations. This disconnect between the agency's messaging and its actual decisions is fueling widespread criticism, investor uncertainty, and accusations of 'moving the goalposts'.

The drama surrounding Sarepta's gene therapy, where a top regulator was ousted after political pushback and later reinstated, shows the FDA is now more amenable to outside influence. This case study indicates that presidential and activist pressure can directly impact regulatory enforcement and personnel decisions, moving beyond purely scientific considerations.

The FDA's quick reversal on reviewing Moderna's flu shot is not a simple policy change. It likely signals deep internal disagreements within the agency, potentially exacerbated by political pressure, which seeks to minimize vaccine-related news ahead of elections.

The key risk facing biomedical innovation is not just policy chaos, but the normalization of political and ideological influences on science-based regulation. This includes CEOs negotiating prices with the president and FDA enforcing pricing policies, breaking long-standing norms that separated science from politics.

The FDA is using unusual public relations tactics, like off-the-record media calls to criticize uniQure and spokespeople arguing on Twitter. This behavior suggests the agency's opposition has moved beyond scientific disagreement into a political and public perception battle, undermining trust in the regulatory process.

FDA Commissioner Macari is facing intense criticism, including from conservative media. This pressure may be compelling the agency to greenlight approvals, particularly for orphan drugs, to appease powerful patient advocacy groups and improve the agency's political standing ahead of potential leadership changes.

Commissioner Marty McCary's unprecedented public discussion of a pending therapy and a director's political affiliations reveal a highly politicized FDA. Describing CBER Director Vinay Prasad as being "on loan" suggests his tenure is fragile and agency leadership is unstable.

The HHS Secretary's unprecedented interview of a candidate for FDA's CEDAR Director marks a significant politicization of a traditionally scientific, civil service position. This shift suggests future directors may need political alignment with the administration, leading to greater risk aversion, erratic decision-making, and less predictability for the biopharma industry.

The focus on Vinay Prasad's personality misses the larger institutional crisis at the FDA: a shift from large, team-based scientific reviews to centralized, politically-influenced decisions made by a few individuals. This 'picking winners and losers' approach undermines the agency's scientific integrity, regardless of who is in charge.